This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H.,
Edland, S. D.,
Teng, E.,
Tingus, K.,
Petersen, R. C.,
Cummings, J. L.
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]
Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension
Grossberg, George,
Sadowsky, Carl,
Fröstl, Hans,
Frölich, Lutz,
Nagel, Jennifer,
Tekin, Sibel,
Zechner, Stefanie,
Ros, Jacqueline,
Orgogozo, Jean-Marc
The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm2) […]
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
Green, Robert C.,
Schneider, Lon S.,
Amato, David A.,
Beelen, Andrew P.,
Wilcock, Gordon,
Swabb, Edward A.,
Zavitz, Kenton H.
Context: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.; Objective: To determine the efficacy, safety, and tolerability of tarenflurbil.; Design, Setting, and Patients: A multicenter, randomized, double-blind, […]
Disclosure of APOE genotype for risk of Alzheimer’s disease
Green, Robert C.,
Roberts, J. Scott,
Cupples, L. Adrienne,
Relkin, Norman R.,
Whitehouse, Peter J.,
Brown, Tamsen,
Eckert, Susan LaRusse,
Butson, Melissa,
Sadovnick, A. Dessa,
Quaid, Kimberly A.,
Chen, Clara,
Cook-Deegan, Robert,
Farrer, Lindsay A.
Background: The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer’s disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure in a prospective, randomized, controlled trial.; Methods: We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer’s disease to receive […]
The Tailored Activity Program to reduce behavioral symptoms in individuals with dementia: feasibility, acceptability, and replication potential
Gitlin, Laura N,
Winter, Laraine,
Vause Earland, Tracey,
Adel Herge, E.,
Chernett, Nancy L.,
Piersol, Catherine V.,
Burke, Janice P.
Purpose: The Tailored Activity Program (TAP) is a home-based occupational therapy intervention shown to reduce behavioral symptoms and caregiver burden in a randomized trial. This article describes TAP, its assessments, acceptability, and replication potential.; Design and Methods: TAP involves 8 sessions for a period of 4 months. Interventionists identify preserved capabilities, previous roles, habits, and […]
Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease
Gehrman, Philip R.,
Connor, Donald J.,
Martin, Jennifer L.,
Shochat, Tamar,
Corey-Bloom, Jody,
Ancoli-Israel, Sonia
Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation.; Design: Randomized, placebo-controlled study.; Setting: Nursing homes in San Diego, CA, metropolitan area.; Participants: Subjects were patients with […]
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach
Ferris, Steven,
Lane, Roger,
Sfikas, Nikolaos,
Winblad, Bengt,
Farlow, Martin,
Feldman, Howard H.
Background: Epidemiologic studies have identified several demographic factors, including gender, that may influence the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD).; Objective: This analysis aimed to develop a sensitive model for detecting treatment benefits in patients with MCI by controlling for factors that predict progression to AD. The study used this statistical […]
Preserving cognition through an integrated cognitive stimulation and training program
Background: Cognitive decline leads to disability and increased health care expenditures.; Methods: Effectiveness of an intervention to stimulate multiple cognitive domains was determined using a format combining traditional and computer-based activities (Integrated Cognitive Stimulation and Training Program), 45 minutes a day, 2 days a week, for 6 weeks. Nonimpaired, mildly, and moderately-impaired participants > age […]
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
Doody, R. S.,
Ferris, S. H.,
Salloway, S.,
Sun, Y.,
Goldman, R.,
Watkins, W. E.,
Xu, Y.,
Murthy, A. K.
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change […]